- Conditions
- Colitis, Ulcerative, Crohn's Disease
- Interventions
- Vedolizumab, Other Biological Agent
- Drug · Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 12,675
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- Aztreonam for Inhalation Solution (AZLI)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Months to 17 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 20 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Lumbar Puncture, Positron Emission Tomography, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 433 more
- Conditions
- Kidney Cancer
- Interventions
- 117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5 (FGF-5):172-176/217-220, IL-2
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
- Interventions
- Lamotrigine, Placebo
- Drug
- Lead sponsor
- Dent Neuroscience Research Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Amherst, New York
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Interventions
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Springdale, Arkansas + 33 more
- Conditions
- CVA (Cerebrovascular Accident), Stroke, Upper Extremity Paresis
- Interventions
- Keys Constraint-induced Movement Therapy protocol
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Schizophrenia
- Interventions
- Visual Training
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
- Interventions
- VIO-01
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas
- Conditions
- Drug Interactions
- Interventions
- Telotristat etiprate, Midazolam
- Drug
- Lead sponsor
- Lexicon Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2014
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Social Anxiety Disorder
- Interventions
- Cognitive Behavioral Group Therapy, Mindfulness-Based Stress Reduction
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Castration-resistant Prostate Cancer Metastatic to Bone
- Interventions
- Blood Tests, CT scan, FACBC PET/MRI in a subset of participants, Radium-223 dichloride, bone scan
- Procedure · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Non-segmental Vitiligo
- Interventions
- VYN201 Gel, Vehicle Gel
- Drug
- Lead sponsor
- Vyne Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 39 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Meal replacement shake
- Dietary Supplement
- Lead sponsor
- Teatis, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Other Drug Substance Abuse
- Interventions
- Iwin: Individual Well-Being Navigator
- Behavioral
- Lead sponsor
- Pro-Change Behavior Systems
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 253 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Watertown, Massachusetts • Poughkeepsie, New York • South Kingstown, Rhode Island + 1 more
- Conditions
- Head and Neck Cancer, Squamous Cell Cancer
- Interventions
- Afatinib, Ribavirin, and weekly carboplatin/paclitaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 2
- States / cities
- Basking Ridge, New Jersey • New York, New York
- Conditions
- HIV (Human Immunodeficiency Virus)
- Interventions
- predictive emergency room alerts (pERA), Standard of care
- Other
- Lead sponsor
- Hunter College of City University of New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
- Interventions
- AVTX-801, Placebo
- Drug
- Lead sponsor
- Eva Morava-Kozicz
- Other
- Eligibility
- 1 Month and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Healthy, Obese
- Interventions
- LY3502970
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin
- Conditions
- Myopia
- Interventions
- OrthoK
- Device
- Lead sponsor
- Illinois College of Optometry
- Other
- Eligibility
- 6 Years to 13 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Parkinson's Disease (PD)
- Interventions
- Low-fidelity driving simulator training
- Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Hypertension
- Interventions
- LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 37
- States / cities
- Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more
- Conditions
- Adenovirus
- Interventions
- Brincidofovir, Standard of Care
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 1 more